What is Brief History of The Oncology Institute Company?

How did The Oncology Institute transform community cancer care?

The Oncology Institute shifted oncology from expensive hospital settings to community-based, value-driven care. Founded in 2007 by Dr. Richy Agajanian, it prioritized evidence-based, cost-effective treatment to reduce financial toxicity for patients and payers.

By 2025 TOI managed care for over 1.8 million lives across 70+ clinics in multiple states, integrating medical oncology, radiation, clinical trials, and an oral dispensary.

What is Brief History of The Oncology Institute Company? Founded in Cerritos, CA in 2007, TOI scaled from one clinic to a public national platform focused on value-based oncology care; see The Oncology Institute Porter's Five Forces Analysis

Founded in 2007 by Dr. Richy Agajanian, the Oncology Institute began as a value-driven alternative to fee-for-service oncology, aiming to create a medical home for cancer patients through capitation and risk-sharing models.

The Founding Story

Dr. Richy Agajanian and a small team launched the Oncology Institute in Whittier and Cerritos, California, to address incentives misaligned in traditional oncology and to standardize care under capitated contracts.

• Founded in 2007 by a board-certified oncologist with internal medicine and hematology training
• Early model emphasized capitation and risk-sharing—a rarity in oncology then
• Bootstrapped initially; sustained by private clinical revenue during validation phase
• Focused on partnerships with IPAs and health plans to offer fixed-cost cancer care

Dr. Agajanian identified inefficiencies in fee-for-service oncology where high-margin drug delivery and hospitalizations were often prioritized; TOI designed internal protocols to manage chemotherapy costs and supportive care, enabling standardized clinical pathways and data-driven outcomes.

By 2008 TOI’s lean operations and managed-care navigation helped it endure the recession; early adoption of value-based oncology supported measurable growth, with the organization negotiating capitated arrangements that reduced per-patient oncology spend versus regional benchmarks by an estimated 15–25% in initial payer contracts.

TOI’s founding team leveraged expertise in California’s managed care regulatory environment to build deep IPA relationships, creating a replicable model that later facilitated institutional scaling and the evolution of Oncology Institute’s timeline toward broader network partnerships.

For additional market analysis and context, see Target Market of The Oncology Institute

Complete The Oncology Institute Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Following its Southern California founding, the Oncology Institute entered a phase of rapid geographic and service-line expansion driven by demonstrated cost savings and scalable community oncology care.

Geographic expansion

Between 2010 and 2018 the Oncology Institute expanded across the California Central Valley and into the Inland Empire, opening dozens of community clinics to meet rising demand.

Value-based savings

The company reduced total oncology care costs for Medicare Advantage plans by 15% to 25% through better management of ER visits and hospital admissions.

Capital infusion

In 2018 General Atlantic provided growth equity that professionalized leadership and funded technology for multi-state operations, accelerating the Oncology Institute company background evolution.

Acquisitions and hybrid strategy

The expansion model shifted to a hybrid of organic clinic openings and strategic acquisitions of smaller independent practices to scale more quickly.

Multi-state replication

By 2021 the Oncology Institute had entered Florida and Nevada, validating that its value-based model and the founding of Oncology Institute approach were replicable beyond California.

Public listing and scale

In late 2021 a SPAC business combination with Deerfield Healthcare Technology Acquisitions Corp. took the company public and provided approximately $330,000,000 in gross proceeds to scale high-touch patient management and clinical trials.

The Oncology Institute timeline shows that by 2024 its clinical trials division had become a meaningful revenue driver, giving community patients access to late-stage therapies; see a concise account in Brief History of The Oncology Institute.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

TOI's milestones trace a path from clinical innovation to scaled specialty care, marked by the proprietary TOI Care pathway, an intensive outpatient program, a specialized oral pharmacy, and a broad clinical trials network, alongside strategic restructurings to improve profitability and operational integration.

TOI's innovations include the TOI Care pathway, which leverages real-world evidence to personalize regimens, and an intensive outpatient model launched in 2022 to keep high-risk patients out of hospitals during vulnerable treatment phases.

TOI Care pathway

The pathway uses aggregated real-world data to prioritize regimens with the best efficacy-toxicity profiles, informing point-of-care decisions.

Intensive outpatient program

Introduced in 2022, the program reduced inpatient stays for high-risk patients and supported continuity during nadir periods.

Specialized oral pharmacy

By 2025 the pharmacy accounted for a substantial share of non-professional revenue, improving adherence and lowering payer costs.

Clinical trials network

Partnerships with top pharmaceutical firms enabled TOI to offer over 170 active clinical trials across its network.

Value-based contracting

Contracts tied to outcomes created long-term payer savings but introduced revenue-timing complexity for quarterly reporting.

Data-driven expansion

Expansion focused on markets with demonstrated patient volume growth, notably Texas and Oregon after 2024 portfolio optimization.

Challenges included public-market timing in 2023 during a volatile period for healthcare stocks and higher interest rates, forcing a refined path to profitability and cash preservation.

Market volatility and financing

Public listing coincided with a downturn in healthcare equities and rising rates, pressuring liquidity and valuation metrics.

Revenue timing

Value-based contract savings often accrue off-quarter, causing mismatch between realized payer savings and reported revenue.

Operational integration

Rapid geographic scale required deeper operational harmonization to protect quality and margins, prompting 2024 restructuring.

Site optimization

Closing underperforming sites improved same-store metrics and strengthened the balance sheet but required upfront restructuring costs.

Clinical scale vs. quality

Balancing expansion with consistent clinical protocols was essential to maintain outcomes while growing patient volume.

Evidence and reimbursement

Demonstrating long-term cost savings to payers remained critical to wider adoption of value-based oncology models.

For a focused look at revenue mix and commercial strategy see Revenue Streams & Business Model of The Oncology Institute.

The Oncology Institute Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

The timeline and future outlook trace the Oncology Institute history from its 2007 founding in Cerritos to projected 2026 GAAP profitability, highlighting geographic expansion, capital raises, clinical-research scale-up, and strategic shifts toward value-based, lower-cost oncology care.

Care Migration and Site-of-Service Shift

Continued migration of oncology care to lower-cost outpatient and clinic settings supports TOI's capitated and clinic-based model, reducing per-patient facility costs and improving access.

Digital Platform Rollout

'TOI Anywhere' aims to integrate telehealth, remote monitoring and ePROs to increase visit throughput and reduce avoidable hospitalizations.

Care-at-Home Expansion

Scaling care-at-home oncology services targets lower-cost infusion alternatives and higher patient convenience while leveraging existing clinic networks for logistics and safety.

AI for Predictive Management

Planned adoption of artificial intelligence to predict patient complications and intervene earlier, aiming to reduce hospital admissions and total cost of care.

For more on the organization’s guiding principles and early mission, see Mission, Vision & Core Values of The Oncology Institute

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE